Novavax has begun a paediatric expansion of its Phase III clinical trial for NVX-CoV2373, a recombinant protein vaccine candidate against the novel coronavirus. The paediatric arm of the PREVENT-19 trial will assess the safety, efficacy and immunogenicity of NVX-CoV2373 in roughly 3,000 adolescents aged 12-17 years across 75 centres in the US. The participants will be randomly allocated either the vaccine candidate or placebo in two doses within a gap of three weeks.
Biopharma company Ocugen has announced that a study by scientists at the Indian Council of Medical Research (ICMR)-National Institute of Virology demonstrated Covaxin’s potential efficacy against the UK, Brazil and Indian double mutant variants of the coronavirus. The study shows that Covaxin-vaccinated sera successfully neutralised the three key variants in an in-vitro plaque reduction neutralisation test. Ocugen is developing Bharat Biotech’s Covaxin for the US market.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Specialty life sciences company Revive Therapeutics has signed a research agreement with the University of California, San Francisco (UCSF) to study bucillamine in treating severe cases of Covid-19. The agreement will support laboratory research to assess the efficacy of bucillamine in pre-clinical models of coronavirus and design procedures to test the drug’s effectiveness in human trials. Bucillamine has previously been investigated for the treatment of rheumatoid arthritis and acute gout.
